Episodes

  • Understanding the Forces Shaping US Health Care

    Understanding the Forces Shaping US Health Care
    Oct 12 2026

    Dr. Jason Crowell talks with Dr. John McDonough about the historical and economic factors shaping the US healthcare system and why understanding these systemic forces matters for neurologists and patient care.

    Read the related article in The Harvard Gazette.

    Disclosures can be found at Neurology.org.

    Show More Show Less
    21 mins
  • Prevalence of CTE at Death in National Football League Players

    Prevalence of CTE at Death in National Football League Players
    Oct 8 2026

    Dr. Shuvro Roy talks with Dr. Daniel Daneshvar about the prevalence of CTE at death among NFL players and the association between CTE severity and the risk of dementia.

    Read the related article in the BMJ.

    Disclosures can be found at Neurology.org.

    Show More Show Less
    25 mins
  • Clinical Manifestations of Primary CNS T Cell Lymphoma

    Clinical Manifestations of Primary CNS T Cell Lymphoma
    Oct 5 2026

    Dr. Kait Nevel talks with Dr. Katharina Schmidbauer about primary CNS T-cell lymphoma, highlighting diagnostic challenges, imaging characteristics, and treatment approaches for this rare disease.

    Read the related article in Neurology®.

    Disclosures can be found at Neurology.org.

    Show More Show Less
    15 mins
  • October 2026 Recall: Updates in Immune-Based Therapies for Neurologic Disease

    October 2026 Recall: Updates in Immune-Based Therapies for Neurologic Disease
    Oct 2 2026

    The October Recall features four previously posted episodes on immune‑based therapies for neurologic disease. In the first episode, Dr. Bhaskar Roy reviews the latest treatments, comparing their efficacy and safety. The second episode, with Dr. Michael Levy, focuses on satralizumab for treating relapsing MOGAD, current management challenges, and the encouraging results of this new therapy. That conversation leads into an episode with Dr. Amanda L. Piquet, who discusses the efficacy and safety of miv-cel in patients with stiff person syndrome. The episode concludes with Dr. Irene Cortese highlighting recent advances in the treatment of PML.

    Podcast links:

    Comparison of the Efficacy and Safety of Myasthenia Gravis Treatments

    Safety and Efficacy of Satralizumab in Patients with Relapsing MOGAD

    Miv-cel CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person Syndrome

    Resolution of PML after Treatment with Virus-Specific T Cells and HCT

    Article links:

    Comparison of the Efficacy and Safety of Myasthenia Gravis Treatments

    Safety and Efficacy of Satralizumab in Patients with Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

    Miv-cel CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person Syndrome in a Pivotal, Multicenter, Phase 2 Study (KYSA-8)

    Resolution of PML after Treatment with Virus-Specific T Cells and HCT

    Disclosures can be found at Neurology.org.

    Show More Show Less
    1 hr and 5 mins
  • The Future of Child Neurology Residency Training

    The Future of Child Neurology Residency Training
    Oct 1 2026

    Dr. Dara Albert talks with Dr. Bruce Cohen about the future of child neurology residency training, exploring current models, consensus areas, and challenges in evolving the curriculum to meet future healthcare needs.

    Read the related article in Neurology® Education.

    Disclosures can be found at Neurology.org.

    Show More Show Less
    22 mins
  • Pharmacologic Treatment for Migraine Prevention in Adults Practice Guideline Recommendations

    Pharmacologic Treatment for Migraine Prevention in Adults Practice Guideline Recommendations
    Sep 28 2026
    Dr. Tesha Monteith talks with Dr. Tamara Pringsheim about the updated American Academy of Neurology (AAN) and American Headache Society (AHS) guidelines on pharmacologic treatment for migraine prevention in adults. Read the related article in Neurology®. Disclosures can be found at Neurology.org. Show transcript: Dr. Jose Merino (00:08): This is Jose Merino, editor-in-chief of the Neurology Family of Journals. The Neurology Podcast provides practical information to neurologists and other clinicians to help them provide better care for their patients. Thanks for listening and have a great week. Dr. Tesha Monteith (00:23): Hi, this is Tesha Monteith with the Neurology Podcast. I'm excited to talk to you today about the update in Migraine Guideline: Pharmacologic Treatment for Migraine Prevention in Adults: Practice Guideline Recommendations, a report of the American Academy Neurology Guidelines Subcommittee, and the American Headache Society. Since the last guideline in 2012, there's been a lot of new advances, including the introduction of CGRP inhibitors for acute and preventive treatment. (00:53): With me to discuss is the lead author, Tamara Pringsheim, a neurologist at the Department of Clinical Neurosciences, Psychiatry, Pediatrics, and Community Health Sciences at the University of Calgary. How are you, Tamara? Dr. Tamara Pringsheim (01:06): Great. Thank you for asking me to talk to you about this. Dr. Tesha Monteith (01:09): Why don't you tell me a little bit about yourself and how you got involved in this work? Dr. Tamara Pringsheim (01:14): Sure. I've been working as a methodologist for the American Academy of Neurology Guidelines Subcommittee for a number of years, since 2015. Prior to that, I was a member of the guideline development subcommittee from 2011. I've worked on a number of different guidelines across neurological conditions. Dr. Tesha Monteith (01:36): Great. So how do these new guidelines compare, just broadly speaking, with the older guidelines? Dr. Tamara Pringsheim (01:43): I guess since the last guidelines were published more than 10 years ago, we've had changes to our methodological process. We had a major update to our guideline process manual in 2017, and guideline methodology has continued to evolve over that time period. And as well, a number of targeted treatments for migraine have come out. So there's been an explosion of evidence, particularly in the last five to seven years. And so we have a whole new class of medications available for migraine prevention, which really target our underlying understanding of the condition, whereas most of the other medications were discovered through serendipity. Dr. Tesha Monteith (02:33): So I know that you reviewed over 200 randomized controlled trials. And so how was the quality or confidence of the evidence determined? Dr. Tamara Pringsheim (02:47): With our process, we start by rating risk of bias for every article. This basically gets at a number of different features related to the clinical trial methodology and reporting, and it helps us determine how confident we are in the evidence. In order for us to be highly confident that the results that we are seeing reflect the truth, we typically need to have at least two Class 1 studies for any intervention outcome pair. The effect size estimate also has to meet a certain threshold in terms of the effect size and the precision surrounding that estimate. So if we feel that based on what the panel decides in terms of what is the minimal clinically important difference between an intervention and placebo, that will help us determine our confidence in the evidence. (03:51): So there's this critical coming together of the number of studies, the quality of studies, the effect size, and the precision of the evidence that helps us determine our confidence in the evidence. And all of this is done behind the scenes using a very algorithmic approach so that these rules are faithfully applied across the different interventions we're looking at. This complexity makes it hard for people to understand why certain drugs land in a certain area, but it's one of the things that we do to make this process standardized and rigorous. Dr. Tesha Monteith (04:37): So I do want to talk to you about that, where drugs have landed. One newer thing was that the review was not just episodic migraine, but also chronic migraine. Dr. Tamara Pringsheim (04:47): Yes. Dr. Tesha Monteith (04:48): Were there important differences in the strength of evidence between these populations? Dr. Tamara Pringsheim (04:53): One thing that's really important to remember is that the use of the term chronic migraine is fairly new. So a lot of the trials of the older headache preventive medications were done in the 80s and the 90s. And at this time, there wasn't a definition which distinguished chronic migraine in particular. So a lot of the trials for amitriptyline, for example, were not done in a purely episodic or chronic ...
    Show More Show Less
    22 mins
  • Primary Motor Cortex Involvement and Seizure Risk in Patients With Brain Metastases

    Primary Motor Cortex Involvement and Seizure Risk in Patients With Brain Metastases
    Sep 21 2026

    Dr. Kait Nevel talks with Drs. Ayal Aizer and Clara Baselga-Garriga about the link between primary motor cortex involvement in brain metastases and increased seizure risk, highlighting implications for patient management and future research directions.

    Read the related article in Neurology®.

    Disclosures can be found at Neurology.org.

    Show More Show Less
    13 mins